Nasdaq:US$18.73 (+0.01) | HKEX:HK$30.75 (+1.05) | AIM:£2.96 (-0.08)
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2017-10-15

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC

JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116)

Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su

Venue: IASLC 18th World Conference on Lung Cancer
Session: JCSE 01 – Joint IASLC / CSCO / CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West (ID 630)
Presenter: J Zhou
Date: Sunday, October 15, 2017

For a summary of the data presented, please see the company overview presentation.